These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31352977)

  • 1. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Butcher G; Howard H; Sathianathen N; Catto JWF; Murphy DG
    Eur Urol; 2019 Dec; 76(6):872-873. PubMed ID: 31352977
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    Taneja SS
    J Urol; 2020 Jan; 203(1):32-33. PubMed ID: 31634064
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Alcaraz A
    Eur Urol; 2020 Feb; 77(2):286-287. PubMed ID: 31522916
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer.
    Huebner NA; Shariat SF
    Eur Urol; 2020 Jan; 77(1):132-133. PubMed ID: 31542306
    [No Abstract]   [Full Text] [Related]  

  • 5. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    Davis ID; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx G; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Sweeney CJ;
    N Engl J Med; 2019 Jul; 381(2):121-131. PubMed ID: 31157964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy.
    Althaus A; Kibel A
    Eur Urol; 2015 Jan; 67(1):174. PubMed ID: 25528395
    [No Abstract]   [Full Text] [Related]  

  • 7. Word of wisdom. Re: enzalutamide in metastatic prostate cancer before chemotherapy.
    Chow K; Murphy DG
    Eur Urol; 2014 Oct; 66(4):785-6. PubMed ID: 25218073
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis.
    Malangone-Monaco E; Foley K; Varker H; Wilson KL; McKenzie S; Ellis L
    Clin Ther; 2016 Aug; 38(8):1817-24. PubMed ID: 27491282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
    Ware KE; Somarelli JA; Schaeffer D; Li J; Zhang T; Park S; Patierno SR; Freedman J; Foo WC; Garcia-Blanco MA; Armstrong AJ
    Oncotarget; 2016 Aug; 7(31):50507-50521. PubMed ID: 27409172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    Taneja SS
    J Urol; 2020 Apr; 203(4):662-663. PubMed ID: 31928459
    [No Abstract]   [Full Text] [Related]  

  • 11. Re:Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    Rubio-Briones J
    Eur Urol; 2020 Apr; 77(4):560-561. PubMed ID: 32029338
    [No Abstract]   [Full Text] [Related]  

  • 12. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
    J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Cabazitaxel Versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    Mori K; Egawa S; Shariat SF
    Eur Urol; 2020 Jun; 77(6):758-759. PubMed ID: 32209284
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Efficacy and Safety of Enzalutamide versus Bicalutamide for Patients with Metastatic Prostate Cancer (TERRAIN): A Randomised, Double-Blind, Phase 2 Study.
    Taneja SS
    J Urol; 2017 Jan; 197(1):152. PubMed ID: 27979508
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Tombal B
    N Engl J Med; 2014 Oct; 371(18):1755-6. PubMed ID: 25354111
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Froehner M; Wirth MP
    N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112
    [No Abstract]   [Full Text] [Related]  

  • 17. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
    Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
    Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
    [No Abstract]   [Full Text] [Related]  

  • 18. [Management of enzalutamide, a new hormonal therapy].
    Beuzeboc P; Benderra MA; de La Motte Rouge T
    Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
    Liu C; Lou W; Zhu Y; Yang JC; Nadiminty N; Gaikwad NW; Evans CP; Gao AC
    Cancer Res; 2015 Apr; 75(7):1413-22. PubMed ID: 25649766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int; 2017 Aug; 120(2):168-184. PubMed ID: 28719114
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.